Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis-Reference-Cited by-同舟云学术

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Published:2017-03-31 Issue:6 Volume:31 Page:1004-1013
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Blauvelt A.¹,Papp K.A.²,Sofen H.³,Augustin M.⁴,Yosipovitch G.⁵,Katoh N.⁶,Mrowietz U.⁷,Ohtsuki M.⁸,Poulin Y.⁹¹⁰,Shrom D.¹¹,Burge R.¹¹,See K.¹¹,Mallbris L.¹¹,Gordon K.B.¹²

Affiliation:

1. Oregon Medical Research Center; Portland OR USA

2. Probity Medical Research and K. Papp Clinical Research; Waterloo ON Canada

3. Department of Medicine (Dermatology); David Geffen School of Medicine; Los Angeles CA USA

4. Institute for Health Services Research in Dermatology and Nursing; University Medical Center Hamburg; Hamburg Germany

5. Department of Dermatology; Miller School of Medicine; University of Miami; Miami FL USA

6. Department of Dermatology; Kyoto Prefectural University of Medicine Graduate School of Medical Science; Kyoto Japan

7. Psoriasis-Center; Department of Dermatology; University Medical Center Schleswig-Holstein; Campus Kiel Germany

8. Department of Dermatology; Jichi Medical University; Shimotsuke Tochigi Japan

9. Department of Medicine; Université Laval; Hôpital Hôtel-Dieu de Québec; Quebec QC Canada

10. Centre de Recherche Dermatologique du Québec Métropolitain; Quebec QC Canada

11. Eli Lilly and Company; Indianapolis IN USA

12. Department of Dermatology; Feinberg School of Medicine; Northwestern University; Chicago IL USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14163/fullpdf

Reference19 articles.

1. Continuous versus intermittent therapy for moderate-to-severe psoriasis;Ramirez-Fort;Clin Exp Rheumatol,2013

2. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy;Brezinski;PLoS ONE,2012

3. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis;Mrowietz;J Eur Acad Dermatol Venereol,2014

4. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy;Papp;Br J Dermatol,2011

5. Duration of remission of biologic agents for chronic plaque psoriasis;Langley;J Drugs Dermatol,2007

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

2. The biological basis of disease recurrence in psoriasis;Italian Journal of Dermatology and Venereology;2023-08

3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

4. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort;Annales de Dermatologie et de Vénéréologie;2023-06

5. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review;Frontiers in Immunology;2023-01-31